An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents

Stroke

Volumn 43, Issue 9, 2012, Pages 2444-2449

  Wang, Yaoming ^a,b   Zhang, Zhenggang ^c   Chow, Nienwen ^d   Davis, Thomas P ^e   Griffin, John H ^f   Chopp, Michael ^c   Zlokovic, Berislav V ^a,b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d ZZ Biotech Research Laboratory   (United States)

^e UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^f SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

ischemic stroke; neuroprotection; proteases; thrombolytic therapy

Indexed keywords

3K3A APC; ALTEPLASE; ANTICOAGULANT AGENT; DROTRECOGIN; NEUROPROTECTIVE AGENT; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION SIZE; BRAIN ISCHEMIA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; HISTOPATHOLOGY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPATHOLOGY; NONHUMAN; PRIORITY JOURNAL; RAT; TREATMENT OUTCOME;

ANIMALS; ANTICOAGULANTS; BRAIN; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; FIBRINOLYTIC AGENTS; HEMOGLOBINS; INFARCTION, MIDDLE CEREBRAL ARTERY; INTRACRANIAL EMBOLISM; MALE; MICE; MICE, INBRED C57BL; NEUROLOGIC EXAMINATION; PROTEIN C; RATS; RATS, WISTAR; STROKE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 84865585576     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.658997     Document Type: Article

References (49)

1. Kleindorfer D, Lindsell CJ, Brass L, Koroshetz W, Broderick JP. National US estimates of recombinant tissue plasminogen activator use: ICD-9 codes substantially underestimate. Stroke. 2008;39:924-928.
2. Cheng T, Petraglia AL, Li Z, Thiyagarajan M, Zhong Z, Wu Z, et al. Activated protein C inhibits tissue plasminogen activator-induced brain hemorrhage. Nat Med. 2006;12:1278-1285.
3. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group. Stroke. 1997;28: 2109-2118.
4. Carpenter CR, Keim SM, Milne WK, Meurer WJ, Barsan WG, Best Evidence in Emergency Medicine Investigator Group. Thrombolytic therapy for acute ischemic stroke beyond three hours. J Emerg Med. 2011;40:82-92.
5. Saver JL, Levine SR. Alteplase for ischaemic stroke-much sooner is much better. Lancet. 2010;375:1667-1668.
6. Nagai N, Vanlinthout I, Collen D. Comparative effects of tissue plasmin-ogen activator, streptokinase, and staphylokinase on cerebral ischemic infarction and pulmonary clot lysis in hamster models. Circulation. 1999; 100:2541-2546.
7. Wang YF, Tsirka SE, Strickland S, Stieg PE, Soriano SG, Lipton SA. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nature medicine. 1998;4:228-231.
8. Liu D, Cheng T, Guo H, Fernandez JA, Griffin JH, Song X, et al. Tissue plasminogen activator neurovascular toxicity is controlled by activated protein C. Nat Med. 2004;10:1379-1383.
9. Zlokovic BV, Griffin JH. Cytoprotective protein C pathways and implications for stroke and neurological disorders. Trends Neurosci. 2011;34: 198-209.
10. Gale AJ, Tsavaler A, Griffin JH. Molecular characterization of an extended binding site for coagulation factor Va in the positive exosite of activated protein C. J Biol Chem. 2002;277:28836-28840.
11. Mosnier LO, Gale AJ, Yegneswaran S, Griffin JH. Activated protein C variants with normal cytoprotective but reduced anticoagulant activity. Blood. 2004;104:1740-1744.
12. Joyce DE, Grinnell BW. Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB. Crit Care Med. 2002;30: S288-S293.
13. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science. 2002;296:1880-1882.
14. Cheng T, Liu D, Griffin JH, Fernandez JA, Castellino F, Rosen ED, et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med. 2003;9: 338-342.
15. Domotor E, Benzakour O, Griffin JH, Yule D, Fukudome K, Zlokovic BV. Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. Blood. 2003;101:4797-4801.
16. Mosnier LO, Griffin JH. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J. 2003;373: 65-70.
17. Feistritzer C, Riewald M. Endothelial barrier protection by activated protein C through PAR1-dependent sphingosine 1-phosphate receptor-1 crossactivation. Blood. 2005;105:3178-3184.
18. Finigan JH, Dudek SM, Singleton PA, Chiang ET, Jacobson JR, Camp SM, et al. Activated protein C mediates novel lung endothelial barrier enhancement: Role of sphingosine 1-phosphate receptor transactivation. J Biol Chem. 2005;280:17286-17293.
19. Deane R, LaRue B, Sagare AP, Castellino FJ, Zhong Z, Zlokovic BV. Endothelial protein C receptor-assisted transport of activated protein C across the mouse blood-brain barrier. J Cerebral Blood Flow Metab. 2009;29:25-33.
20. Zhong Z, Ilieva H, Hallagan L, Bell R, Singh I, Paquette N, et al. Activated protein C therapy slows ALS-like disease in mice by transcrip-tionally inhibiting SOD1 in motor neurons and microglia cells. J Clin Invest. 2009;119:3437-3449.
21. Esmon CT, Glass JD. The APCs of neuroprotection. J Clin Invest. 2009;119:3205-3207.
22. Guo H, Liu D, Gelbard H, Cheng T, Insalaco R, Fernandez JA, et al. Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3. Neuron. 2004;41:563-572.
23. Guo H, Singh I, Wang Y, Deane R, Barrett T, Fernandez JA, et al. Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity. Eur J Neurosci. 2009;29:1119-1130.
24. Shibata M, Kumar SR, Amar A, Fernandez JA, Hofman F, Griffin JH, et al. Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke. Circulation. 2001;103:1799-1805.
25. Thiyagarajan M, Fernandez JA, Lane SM, Griffin JH, Zlokovic BV. Activated protein C promotes neovascularization and neurogenesis in postischemic brain via protease-activated receptor 1. J Neurosci. 2008; 28:12788-12797.
26. Wang Y, Thiyagarajan M, Chow N, Singh I, Guo H, Davis TP, et al. Differential neuroprotection and risk for bleeding from activated protein C with varying degrees of anticoagulant activity. Stroke. 2009;40: 1864-1869.
27. Zlokovic BV, Zhang C, Liu D, Fernandez J, Griffin JH, Chopp M. Functional recovery after embolic stroke in rodents by activated protein C. Ann Neurol. 2005;58:474-477.
28. Yesilirmak DC, Kumral A, Tugyan K, Cilaker S, Baskin H, Yilmaz O, et al. Effects of activated protein C on neonatal hypoxic ischemic brain injury. Brain research. 2008;1210:56-62.
29. Sumii T, Lo EH. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke. 2002;33:831-836.
30. Zhang L, Zhang ZG, Zhang C, Zhang RL, Chopp M. Intravenous administration of a GPIIb/IIIa receptor antagonist extends the therapeutic window of intra-arterial tenecteplase-tissue plasminogen activator in a rat stroke model. Stroke. 2004;35:2890-2895.
31. Walker CT, Marky AH, Petraglia AL, Ali T, Chow N, Zlokovic BV. Activated protein C analog with reduced anticoagulant activity improves functional recovery and reduces bleeding risk following controlled cortical impact. Brain Res. 2010;1347:125-131.
32. Guo H, Wang Y, Singh I, Liu D, Fernandez JA, Griffin JH, et al. Species-dependent neuroprotection by activated protein C mutants with reduced anticoagulant activity. J Neurochem. 2009;109:116-124.
33. van Bruggen N, Thibodeaux H, Palmer JT, Lee WP, Fu L, Cairns B, et al. VEGF antagonism reduces edema formation and tissue damage after ischemia/reperfusion injury in the mouse brain. J Clin Invest. 1999;104: 1613-1620.
34. Hoang S, Liauw J, Choi M, Guzman RG, Steinberg GK. Netrin-4 enhances angiogenesis and neurologic outcome after cerebral ischemia. J Cerebral Blood Flow Metab. 2009;29:385-397.
35. Zhang RL, Chopp M, Zhang ZG, Jiang Q, Ewing Jr. A rat model of focal embolic cerebral ischemia. Brain Res. 1997;766:83-92.
36. Chen J, Li Y, Wang L, Zhang Z, Lu D, Lu M, et al. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke. 2001;32:1005-1011.
37. Gong Y, Hua Y, Keep RF, Hoff JT, Xi G. Intracerebral hemorrhage: Effects of aging on brain edema and neurological deficits. Stroke. 2004; 35:2571-2575.
38. Swanson RA, Morton MT, Tsao-Wu G, Savalos RA, Davidson C, Sharp FR. A semiautomated method for measuring brain infarct volume. J Cerebral Blood Flow Metab. 1990;10:290-293.
39. Wang Y, Kilic E, Kilic U, Weber B, Bassetti CL, Marti HH, et al. Vegf overexpression induces post-ischaemic neuroprotection, but facilitates haemodynamic steal phenomena. Brain. 2005;128:52-63.
40. Choudhri TF, Hoh BL, Solomon RA, Connolly ES Jr, Pinsky DJ. Use of a spectrophotometric hemoglobin assay to objectively quantify intracere-bral hemorrhage in mice. Stroke. 1997;28:2296-2302.
41. Yepes M, Sandkvist M, Moore EG, Bugge TH, Strickland DK, Lawrence DA. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest. 2003;112:1533-1540.
42. Yepes M, Roussel BD, Ali C, Vivien D. Tissue-type plasminogen activator in the ischemic brain: More than a thrombolytic. Trends Neurosci. 2009;32:48-55.
43. Ding G, Jiang Q, Zhang L, Zhang ZG, Li L, Knight RA, et al. Analysis of combined treatment of embolic stroke in rat with r-tPA and a GPIIb/IIIa inhibitor. J Cerebral Blood Flow Metab. 2005;25: 87-97.
44. Overgaard K, Sereghy T, Boysen G, Pedersen H, Diemer NH. Reduction of infarct volume and mortality by thrombolysis in a rat embolic stroke model. Stroke. 1992;23:1167-1173; discussion 1174.
45. Zhu Y, Carmeliet P, Fay WP. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance. Circulation. 1999;99:3050-3055.
46. Klein GM, Li H, Sun P, Buchan AM. Tissue plasminogen activator does not increase neuronal damage in rat models of global and focal ischemia. Neurology. 1999;52:1381-1384.
47. Marder VJ, Jahan R, Gruber T, Goyal A, Arora V. Thrombolysis with plasmin: Implications for stroke treatment. Stroke. 2010;41:S45-S49.
48. Jiang Q, Zhang RL, Zhang ZG, Ewing JR, Jiang P, Divine GW, et al. Magnetic resonance imaging indexes of therapeutic efficacy of recombinant tissue plasminogen activator treatment of rat at 1 and 4 hours after embolic stroke. J Cerebral Blood Flow Metab. 2000;20:21-27.
49. Kerschen EJ, Fernandez JA, Cooley BC, Yang XV, Sood R, Mosnier LO, et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med. 2007;204:2439-2448.